NEO,RYTM Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.08
Percentage change -0.98	%

Peers: ILMN LH DGX BIO QGEN EXAS NVCR GH TMO A

| Held by: IJR VTI VB IWM VXF VBK SPSM IWN VTWO IJS

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	1.22%	Shs Outstand	128.36M	Perf Week	4.55%
Market Cap	1.04B	Forward P/E	26.90	EPS next Y	0.30	Insider Trans	3.92%	Shs Float	127.13M	Perf Month	-11.73%
Income	-77.59M	PEG	-	EPS next Q	0.03	Inst Own	98.50%	Short Float	3.92%	Perf Quarter	-40.15%
Sales	672.36M	P/S	1.54	EPS this Y	38.18%	Inst Trans	1.29%	Short Ratio	2.40	Perf Half Y	-46.08%
Book/sh	6.92	P/B	1.16	EPS next Y	96.90%	ROA	-4.79%	Short Interest	4.98M	Perf Year	-48.30%
Cash/sh	2.78	P/C	2.89	EPS next 5Y	66.44%	ROE	-8.57%	52W Range	6.08 - 19.11	Perf YTD	-51.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-6.02%	52W High	-57.89%	Beta	1.63
Dividend TTM	-	Quick Ratio	1.94	Sales past 5Y	10.13%	Gross Margin	41.52%	52W Low	32.40%	ATR (14)	0.72
Dividend Ex-Date	-	Current Ratio	2.05	EPS Y/Y TTM	8.79%	Oper. Margin	-12.01%	RSI (14)	43.35	Volatility	5.95% 9.01%
Employees	2200	Debt/Eq	0.68	Sales Y/Y TTM	10.10%	Profit Margin	-11.54%	Recom	1.80	Target Price	10.62
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	5.17%	Payout	-	Rel Volume	0.46	Prev Close	8.13
Sales Surprise	-1.49%	EPS Surprise	100.00%	Sales Q/Q	7.55%	Earnings	Apr 29 BMO	Avg Volume	2.07M	Price	8.05
SMA20	-7.93%	SMA50	-13.02%	SMA200	-41.68%	Trades		Volume	958,132	Change	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-25	Downgrade	Leerink Partners	Outperform → Market Perform	$9
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy	$22
May-01-24	Resumed	Craig Hallum	Buy	$26
Dec-29-23	Reiterated	BTIG Research	Buy	$25 → $21
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight	$18
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy	$25
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy	$20
Feb-01-23	Upgrade	Needham	Hold → Buy	$15
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight	$13
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight	$34 → $16
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral	$25 → $18
Jan-18-22	Resumed	Stephens	Overweight	$40
Dec-16-21	Initiated	Cowen	Outperform	$42
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$53
Jun-03-21	Initiated	Goldman	Buy	$55

Show Previous Ratings

May-06-25 09:30AM	It's Not Too Late to Jump on These Under-the-Radar Momentum Plays (MarketBeat)
May-05-25 12:34AM	3 Small-Cap Stocks Walking a Fine Line (StockStory)
May-01-25 11:55AM	NeoGenomics price target lowered to $10 from $17 at Morgan Stanley (TipRanks) +13.53%
07:05AM	NeoGenomics Pays Off 1.25% Convertible Senior Notes (Business Wire)
Apr-30-25 09:00AM	NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) (Seeking Alpha)
03:09AM	Loading…
03:09AM	NeoGenomics Inc (NEO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-29-25 03:49PM	Why NeoGenomics (NEO) Stock Is Nosediving (StockStory) -34.00%
12:18PM	NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:40AM	NeoGenomics (NEO) Reports Break-Even Earnings for Q1 (Zacks)
08:00AM	NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform (PR Newswire)
07:56AM	NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops (StockStory)
07:42AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2025 Results (Business Wire)
Apr-28-25 03:01AM	NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-23-25 10:01AM	Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for (Zacks)
10:00AM	Loading…
Apr-22-25 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:05AM	NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting (Business Wire)
Apr-08-25 07:05AM	NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 (Business Wire) -7.13%
Apr-07-25 07:05AM	NeoGenomics Completes Acquisition of Pathline (Business Wire)
Apr-03-25 05:06AM	Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) (StockStory) -7.43%
Apr-01-25 07:05AM	Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics (Business Wire)
Mar-21-25 05:10AM	3 Reasons to Sell NEO and 1 Stock to Buy Instead (StockStory)
Mar-18-25 07:05AM	NeoGenomics Appoints Warren Stone as President & Chief Operating Officer (Business Wire)
Mar-14-25 05:08AM	Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX) (StockStory)
Mar-12-25 12:43PM	3 Small-Cap Stocks in Hot Water (StockStory) -5.97%
Mar-10-25 07:00AM	NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline (Business Wire) -10.05%
Feb-28-25 08:02AM	3 Healthcare Stocks Skating on Thin Ice (StockStory)
Feb-24-25 07:05AM	NeoGenomics to Participate in Upcoming Investor Conferences (Business Wire)
Feb-19-25 02:03AM	NeoGenomics Inc (NEO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-18-25 11:33PM	Q4 2024 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents) -13.97%
12:46PM	Loading…
12:46PM	Why NeoGenomics (NEO) Shares Are Trading Lower Today (StockStory)
08:15AM	NeoGenomics (NEO) Tops Q4 Earnings Estimates (Zacks)
07:24AM	NeoGenomics: Q4 Earnings Snapshot (Associated Press Finance)
07:13AM	NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets (StockStory)
07:05AM	NeoGenomics Reports Fourth Quarter and Full Year 2024 Results (Business Wire)
Feb-17-25 08:13AM	NeoGenomics (NEO) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Feb-12-25 09:56AM	Q4 2024 Adaptive Biotechnologies Corp Earnings Call (Thomson Reuters StreetEvents)
Jan-30-25 09:05AM	PacBio Announces Appointment of Chris Smith to Board of Directors (GlobeNewswire)
Jan-29-25 08:05AM	NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 (Business Wire)
Jan-15-25 04:24PM	NeoGenomics Is On The Upswing, Reversing A CEO-Tied Sell-Off, On Bullish Long-Term Guidance (Investor's Business Daily) +6.75%
10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:05AM	NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan (Business Wire)
04:53AM	NeoGenomics (NEO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
Jan-14-25 07:30AM	Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients (GlobeNewswire) +9.11%
Jan-10-25 07:05AM	NeoGenomics Announces Chief Executive Officer Succession (Business Wire) -20.63%
Jan-06-25 07:55AM	NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-24 12:00PM	NeoGenomics (NEO) Upgraded to Buy: Here's Why (Zacks)
Dec-11-24 08:05AM	NeoGenomics Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma (Business Wire)
Dec-09-24 08:10AM	NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting (Business Wire)
Dec-05-24 07:00AM	ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research (Business Wire)
Nov-19-24 08:15AM	NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Nov-14-24 08:10AM	Felicia Williams Joins NeoGenomics Board of Directors (Business Wire)
Nov-08-24 07:00AM	NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-06-24 12:00PM	NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
02:24AM	Q3 2024 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-05-24 10:00AM	NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +5.59%
07:23AM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	NeoGenomics Reports Third Quarter 2024 Results (Business Wire)
Nov-04-24 09:55AM	Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade (Zacks)
Oct-23-24 05:37AM	NeoGenomics gains conditional approval for solid tumour assays in New York (Medical Device Network)
Oct-22-24 08:10AM	NeoGenomics Receives New York State Approval for Neo Comprehensive Solid Tumor Test (Business Wire)
Oct-15-24 07:30AM	NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 (Business Wire)
Oct-08-24 09:55AM	NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:10AM	NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia (Business Wire)
Sep-23-24 06:47PM	NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation (Business Wire)
Sep-11-24 08:05AM	NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Aug-29-24 08:05AM	NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Jul-29-24 06:00PM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings (Zacks) +17.96%
04:33PM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	NeoGenomics Reports Second Quarter 2024 Results (Business Wire)
Jul-20-24 08:09AM	Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years? (Insider Monkey)
Jul-09-24 07:00AM	NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024 (Business Wire)
Jun-13-24 08:00AM	Fort Myers Mayor to Proclaim June as NeoGenomics Commitment to Cancer Month (Business Wire)
Jun-10-24 01:00AM	Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing (GlobeNewswire)
May-28-24 08:05AM	NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management (Business Wire)
May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.44%
May-01-24 03:04AM	NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
Apr-30-24 11:53AM	NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -8.54%
11:25AM	Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating (MT Newswires)
10:30AM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings (Zacks)
08:52AM	NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
08:40AM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:37AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2024 Results (Business Wire)
Apr-23-24 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) +5.51%
Apr-18-24 07:05AM	NeoGenomics Announces Senior Leadership Promotions (Business Wire)
Apr-09-24 07:00AM	NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024 (Business Wire)
Mar-27-24 08:30AM	NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting (Business Wire)
Mar-20-24 12:00PM	All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy (Zacks) +5.57%
09:55AM	Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect? (Zacks)
07:00AM	NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report (Business Wire)
Mar-01-24 07:05AM	NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-29-24 08:12AM	Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:55AM	Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know (Zacks)
Feb-21-24 09:57AM	NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.11%
06:38AM	Q4 2023 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 07:00PM	NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:39PM	NeoGenomics Inc (NEO) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full Year 2023 (GuruFocus.com)

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TETRAULT LYNN A.	Director	May 09 '25	Buy	8.14	7,000	56,974	7,000	May 09 05:26 PM
KANOVSKY STEPHEN M	Director	May 07 '25	Buy	7.78	4,000	31,124	40,090	May 09 05:24 PM
Zook Anthony P.	Chief Executive Officer	May 06 '25	Buy	7.88	18,900	148,919	18,900	May 08 04:13 PM
Perez David Brian	Director	May 05 '25	Buy	7.63	10,000	76,300	10,000	May 07 04:05 PM
Gunn Neil	Director	May 05 '25	Buy	7.75	4,510	34,977	15,846	May 07 04:05 PM
Sherman Jeffrey Scott	Chief Financial Officer	May 02 '25	Buy	7.51	20,000	150,104	158,494	May 06 04:08 PM
Stone Warren	Pres & Chief Operating Officer	May 02 '25	Option Exercise	0.00	5,969	0	96,762	May 06 04:07 PM
Aunan Greg D	Chief Accounting Officer	May 02 '25	Option Exercise	0.00	5,372	0	18,888	May 05 04:06 PM
Olivo Alicia C	EVP, GC & Business Development	Feb 23 '25	Option Exercise	0.00	8,443	0	47,857	Feb 25 04:41 PM
Harris Melody	Chf Ops Off, Pres, Informatics	Feb 23 '25	Option Exercise	0.00	8,443	0	111,811	Feb 25 04:40 PM
Stone Warren	Chief Commerical Officer	Feb 23 '25	Option Exercise	0.00	8,443	0	93,265	Feb 25 04:39 PM
Sherman Jeffrey Scott	Chief Financial Officer	Feb 23 '25	Option Exercise	0.00	15,535	0	141,271	Feb 25 04:38 PM
Smith Christopher M	Chief Executive Officer	Feb 23 '25	Option Exercise	0.00	57,413	0	655,652	Feb 25 04:37 PM
Olivo Alicia C	General Counsel	Nov 15 '24	Sale	15.36	5,175	79,475	37,129	Nov 19 05:43 PM
ALICIA OLIVO	Officer	Nov 15 '24	Proposed Sale	15.79	5,175	81,713		Nov 15 04:35 PM
Olivo Alicia C	General Counsel	Aug 15 '24	Sale	16.05	1,040	16,695	43,813	Aug 19 04:17 PM
ALICIA OLIVO	Officer	Aug 15 '24	Proposed Sale	15.82	1,040	16,453		Aug 15 04:29 PM
BRUCE K CROWTHER	Officer	Aug 15 '24	Proposed Sale	15.95	8,353	133,243		Aug 15 04:12 PM
Zook Anthony P.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:40 PM
TETRAULT LYNN A.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	61,398	Aug 13 04:37 PM
Perez David Brian	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	21,636	Aug 13 04:34 PM
Kelly Michael Aaron	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	31,755	Aug 13 04:32 PM
KANOVSKY STEPHEN M	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	36,090	Aug 13 04:27 PM
HANNAH ALISON L.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	118,769	Aug 13 04:24 PM
Gunn Neil	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:21 PM
Floegel Elizabeth	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:17 PM
Olivo Alicia C	General Counsel	May 15 '24	Sale	15.74	1,049	16,511	44,867	May 17 04:07 PM
Smith Christopher M	Chief Executive Officer	May 11 '24	Option Exercise	0.00	96,126	0	679,432	May 14 09:39 PM
Olivo Alicia C	General Counsel	May 11 '24	Option Exercise	0.00	13,004	0	45,916	May 14 09:39 PM
Stone Warren	Chief Commerical Officer	May 11 '24	Option Exercise	0.00	19,224	0	100,658	May 14 09:38 PM
Sherman Jeffrey Scott	Chief Financial Officer	May 11 '24	Option Exercise	0.00	26,010	0	148,505	May 14 09:38 PM
Harris Melody	Chf Ops Off, Pres, Informatics	May 11 '24	Option Exercise	0.00	7,068	0	110,023	May 14 09:38 PM

Dollar change -3.34
Percentage change -5.50	%

RYTM Rhythm Pharmaceuticals Inc daily Stock Chart

Peers: PFE VRTX MRK NVO SNY LLY TAK VTRS XENE NBIX

| Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-2.82	Insider Own	9.96%	Shs Outstand	63.49M	Perf Week	-10.36%
Market Cap	3.65B	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-3.79%	Shs Float	57.29M	Perf Month	-4.73%
Income	-173.99M	PEG	-	EPS next Q	-0.64	Inst Own	94.46%	Short Float	8.92%	Perf Quarter	-3.04%
Sales	136.86M	P/S	26.67	EPS this Y	37.85%	Inst Trans	-5.32%	Short Ratio	7.34	Perf Half Y	2.01%
Book/sh	0.30	P/B	192.29	EPS next Y	47.45%	ROA	-52.28%	Short Interest	5.11M	Perf Year	45.82%
Cash/sh	4.94	P/C	11.61	EPS next 5Y	-	ROE	-418.97%	52W Range	35.17 - 68.58	Perf YTD	2.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.34%	ROI	-63.30%	52W High	-16.33%	Beta	2.39
Dividend TTM	-	Quick Ratio	3.13	Sales past 5Y	189.02%	Gross Margin	89.12%	52W Low	63.15%	ATR (14)	3.39
Dividend Ex-Date	-	Current Ratio	3.30	EPS Y/Y TTM	39.30%	Oper. Margin	-126.13%	RSI (14)	43.00	Volatility	6.80% 4.94%
Employees	283	Debt/Eq	13.60	Sales Y/Y TTM	48.88%	Profit Margin	-127.12%	Recom	1.00	Target Price	82.08
Option/Short	Yes / Yes	LT Debt/Eq	13.50	EPS Q/Q	65.72%	Payout	-	Rel Volume	1.28	Prev Close	60.72
Sales Surprise	-18.57%	EPS Surprise	-16.68%	Sales Q/Q	25.94%	Earnings	May 07 BMO	Avg Volume	695.62K	Price	57.38
SMA20	-7.72%	SMA50	1.43%	SMA200	5.77%	Trades		Volume	888,213	Change	-5.50%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy	$63
Mar-05-25	Resumed	Stifel	Buy	$78
Jan-02-25	Initiated	Jefferies	Buy	$80
Dec-20-24	Initiated	Oppenheimer	Outperform	$76
Oct-21-24	Initiated	Guggenheim	Buy	$70
Sep-18-24	Initiated	H.C. Wainwright	Buy	$64
Sep-17-24	Initiated	JMP Securities	Mkt Outperform	$64
May-08-24	Downgrade	BofA Securities	Buy → Neutral	$49 → $42
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$29 → $55
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy	$22 → $27
Jan-18-23	Resumed	Canaccord Genuity	Buy	$52
Aug-08-22	Upgrade	Goldman	Neutral → Buy	$28
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral	$8 → $20
Jun-17-22	Reiterated	Needham	Buy	$40 → $25
Mar-02-22	Resumed	Stifel	Buy	$23
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy	$15
Dec-08-21	Initiated	Wells Fargo	Overweight	$30
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$50 → $15
Sep-14-21	Resumed	Goldman	Neutral	$14
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral

Show Previous Ratings

May-08-25 03:10AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... (GuruFocus.com) -6.05%
May-07-25 03:22PM	Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment (Seeking Alpha)
03:21PM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
08:00AM	Loading…
May-06-25 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-01-25 10:01AM	Analysts Estimate Wave Life Sciences (WVE) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-30-25 10:01AM	Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-23-25 08:00AM	Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 (GlobeNewswire)
Apr-08-25 03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +5.04%
01:38PM	Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (Seeking Alpha)
12:10PM	5 Stocks in Nasdaq ETF Fueling Index's Big Comeback Since 2008 (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
07:09AM	Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? (Zacks)
04:09PM	Loading…
Apr-07-25 04:09PM	This Obesity Drug Just Crushed Expectations -- And Sent One Biotech Stock Soaring 14.5% (GuruFocus.com) +17.06%
12:30PM	Rhythm seeks market expansion for Imcivree following Phase III victory (Clinical Trials Arena)
12:23PM	Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder (Benzinga)
07:51AM	Obesity drug data helps Rhythm defy market slide (BioPharma Dive)
07:00AM	Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity (GlobeNewswire)
Apr-06-25 12:00PM	Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity (GlobeNewswire)
Mar-20-25 04:55PM	Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
04:01PM	Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE (setmelanotide) in China with Termination of Agreement with RareStone Ltd. (GlobeNewswire)
Mar-19-25 04:23PM	Rhythm Pharmaceuticals gets Orphan Drug status for its hypothalamic obesity treatment in Japan (SeekingAlpha) +5.58%
04:01PM	Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan (GlobeNewswire)
Mar-18-25 07:00AM	Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration (GlobeNewswire)
Feb-27-25 02:07AM	Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
12:38AM	Q4 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 08:25AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
04:58PM	Loading…
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily)
Feb-13-25 08:00AM	Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 (GlobeNewswire)
Feb-05-25 08:00AM	Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February (GlobeNewswire)
Jan-28-25 09:55AM	Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet (Zacks)
Jan-22-25 08:50AM	Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Jan-10-25 07:15AM	Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones (GlobeNewswire)
Jan-02-25 10:15AM	Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential (TipRanks) +7.31%
Dec-20-24 02:24PM	Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential (Benzinga)
02:15PM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) for Patients as Young as 2 Years Old (GlobeNewswire)
Dec-06-24 06:48AM	Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities (TipRanks)
Dec-03-24 06:00AM	Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old (GlobeNewswire)
Nov-18-24 12:02PM	Biotech Stock Attempts To End Losing Streak, Lands Back in Buy Zone (Investor's Business Daily)
07:00AM	Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide (GlobeNewswire)
Nov-13-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology (GlobeNewswire) -6.23%
04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Nov-07-24 02:29AM	Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-24 08:00AM	Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences (GlobeNewswire) +11.38%
Nov-05-24 05:10PM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +6.15%
04:01PM	Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 04:01PM	Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 (GlobeNewswire) +8.12%
Oct-29-24 10:01AM	Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-24-24 06:00AM	Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome (GlobeNewswire)
Oct-23-24 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 (GlobeNewswire)
Oct-08-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Sep-21-24 02:23AM	Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish (Insider Monkey)
Sep-18-24 10:46AM	Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? (Zacks)
Sep-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +7.37%
Sep-10-24 01:55PM	Biotech Stock Near Buy Point Amid Impressive Sales Track Record (Investor's Business Daily)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
Aug-26-24 08:02AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE (setmelanotide) in Patients as Young as 2 years old (GlobeNewswire) +8.41%
08:00AM	Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September (GlobeNewswire)
Aug-13-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Aug-06-24 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Jul-31-24 09:10AM	Rhythm Pharmaceuticals Announces European Commission Expands IMCIVREE (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old (GlobeNewswire)
Jul-23-24 08:00AM	Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity (GlobeNewswire)
07:30AM	Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 (GlobeNewswire)
Jul-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.00% +7.34%
Jul-08-24 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Jun-28-24 08:00AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency (GlobeNewswire)
Jun-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire) +5.36%
Jun-03-24 04:02PM	Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 (GlobeNewswire) +6.08%
08:02AM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference (GlobeNewswire)
May-22-24 04:00AM	Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for IMCIVREE (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome (GlobeNewswire)
May-09-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
May-08-24 10:51AM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:06AM	Rhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ... (GuruFocus.com)
May-07-24 10:34PM	Q1 2024 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -10.32%
02:52PM	The 3 Best Nasdaq Stocks to Buy in May 2024 (InvestorPlace)
08:58AM	Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell (MT Newswires)
08:36AM	Rhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst Challenges (GuruFocus.com)
08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting (GlobeNewswire)
Apr-30-24 10:01AM	Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline (Zacks)
Apr-29-24 06:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology (GlobeNewswire)
Apr-28-24 09:20AM	Jim Cramer Portfolio: 11 Latest Stocks to Buy (Insider Monkey)
Apr-24-24 04:01PM	Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (GlobeNewswire)
Apr-16-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-24 08:00AM	Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing (GlobeNewswire)
Mar-25-24 08:00AM	Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist (GlobeNewswire)
Mar-22-24 07:01PM	Chief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-20-24 01:49AM	Insider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 Shares (GuruFocus.com)
01:49AM	Insider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ... (GuruFocus.com)
01:49AM	Insider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM) (GuruFocus.com)
Mar-11-24 04:01PM	Rhythm Pharmaceuticals Announces New Employment Inducement Grants (GlobeNewswire)
Mar-06-24 04:01PM	Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 12:04PM	Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 10:19PM	Q4 2023 Rhythm Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.73%
08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates (Zacks)

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Option Exercise	6.80	7,031	47,811	26,240	May 01 04:53 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 29 '25	Sale	65.09	7,031	457,663	19,209	May 01 04:53 PM
Mazabraud Yann	EVP, Head of International	Apr 29 '25	Sale	65.08	6,745	438,946	37,655	May 01 04:52 PM
YANN MAZZABRAUD	Officer	Apr 29 '25	Proposed Sale	64.41	6,745	434,445		Apr 29 04:21 PM
PAMELA CRAMER	Officer	Apr 29 '25	Proposed Sale	64.41	7,031	452,867		Apr 29 04:20 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Option Exercise	13.43	20,760	278,853	39,969	Apr 10 05:17 PM
Cramer Pamela J.	Chief Human Resources Officer	Apr 08 '25	Sale	60.14	20,760	1,248,490	19,209	Apr 10 05:17 PM
Mazabraud Yann	EVP, Head of International	Apr 08 '25	Sale	60.99	17,750	1,082,497	22,620	Apr 10 05:16 PM
PAMELA CRAMER	Officer	Apr 08 '25	Proposed Sale	54.96	20,760	1,140,970		Apr 08 04:18 PM
YANN MAZZABRAUD	Officer	Apr 08 '25	Proposed Sale	54.96	17,750	975,540		Apr 08 04:16 PM
German Christopher Paul	Corporate Controller & CAO	Mar 21 '25	Sale	54.23	344	18,655	2,889	Mar 24 05:47 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Option Exercise	22.28	75,000	1,671,000	115,370	Mar 18 09:16 PM
Mazabraud Yann	EVP, Head of International	Mar 14 '25	Sale	51.48	75,000	3,861,272	40,370	Mar 18 09:16 PM
YANN MAZZABRAUD	Officer	Mar 14 '25	Proposed Sale	50.24	75,000	3,768,000		Mar 14 04:21 PM
Smith Hunter C	Chief Financial Officer	Feb 19 '25	Sale	57.22	2,215	126,742	109,929	Feb 19 09:50 PM
Shulman Joseph	Chief Technical Officer	Feb 19 '25	Sale	57.22	1,228	70,266	8,509	Feb 19 09:49 PM
Meeker David P	President and CEO	Feb 19 '25	Sale	57.22	9,896	566,249	201,281	Feb 19 09:48 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 19 '25	Sale	57.22	2,035	116,443	5,858	Feb 19 09:46 PM
German Christopher Paul	Corporate Controller & CAO	Feb 19 '25	Sale	57.22	635	36,335	2,070	Feb 19 09:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 19 '25	Sale	57.22	982	56,190	19,209	Feb 19 09:43 PM
Smith Hunter C	Chief Financial Officer	Feb 12 '25	Sale	56.39	751	42,347	105,544	Feb 14 04:59 PM
Shulman Joseph	Chief Technical Officer	Feb 12 '25	Sale	56.40	469	26,452	5,612	Feb 14 04:57 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 12 '25	Sale	56.39	1,815	102,348	3,598	Feb 14 04:55 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 13 '25	Sale	58.00	1,205	69,890	2,393	Feb 14 04:55 PM
JENNIFER KAYDEN LEE	Officer	Feb 13 '25	Proposed Sale	57.64	1,205	69,456		Feb 13 04:31 PM
JENNIFER KAYDEN LEE	Officer	Feb 12 '25	Proposed Sale	57.58	1,205	69,384		Feb 12 04:42 PM
Shulman Joseph	Chief Technical Officer	Feb 11 '25	Sale	57.51	794	45,663	6	Feb 11 09:47 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 09 '25	Option Exercise	6.80	4,189	28,485	8,598	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 10 '25	Sale	58.91	4,189	246,783	4,409	Feb 11 09:46 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 11 '25	Sale	57.51	1,027	59,063	5,413	Feb 11 09:46 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 11 '25	Sale	57.51	701	40,315	16,891	Feb 11 09:45 PM
Smith Hunter C	Chief Financial Officer	Feb 11 '25	Sale	57.51	1,296	74,533	106,295	Feb 11 09:44 PM
JENNIFER KAYDEN LEE	Officer	Feb 10 '25	Proposed Sale	59.18	4,189	247,905		Feb 10 04:34 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 05 '25	Sale	60.55	3,066	185,640	972	Feb 07 05:05 PM
JENNIFER KAYDEN LEE	Officer	Feb 05 '25	Proposed Sale	59.95	3,066	183,807		Feb 05 04:20 PM
Smith Hunter C	Chief Financial Officer	Feb 04 '25	Sale	59.43	1,678	99,724	101,186	Feb 04 09:27 PM
Shulman Joseph	Chief Technical Officer	Feb 04 '25	Sale	59.43	1,281	76,130	2,657	Feb 04 09:26 PM
Meeker David P	President and CEO	Feb 04 '25	Sale	59.43	4,278	254,242	189,927	Feb 04 09:25 PM
Lee Jennifer Kayden	EVP, Head of North America	Feb 04 '25	Sale	59.43	1,447	85,995	4,038	Feb 04 09:23 PM
Cramer Pamela J.	Chief Human Resources Officer	Feb 04 '25	Sale	59.43	902	53,606	15,248	Feb 04 09:22 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Option Exercise	19.59	60,981	1,194,709	67,833	Nov 13 09:04 PM
Lee Jennifer Kayden	EVP, Head of North America	Nov 11 '24	Sale	66.33	66,861	4,434,882	972	Nov 13 09:04 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Option Exercise	12.63	13,281	167,760	13,281	Nov 13 09:02 PM
Shulman Joseph	Chief Technical Officer	Nov 11 '24	Sale	66.44	13,281	882,341	0	Nov 13 09:02 PM
JENNIFER KAYDEN LEE	Officer	Nov 11 '24	Proposed Sale	67.33	66,861	4,501,751		Nov 12 07:55 AM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Option Exercise	19.02	4,688	89,166	18,188	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Option Exercise	19.02	4,687	89,147	18,187	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 07 '24	Sale	65.00	4,688	304,720	13,500	Nov 08 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Nov 06 '24	Sale	60.00	4,687	281,220	13,500	Nov 08 04:15 PM
PAMELA CRAMER	Officer	Nov 07 '24	Proposed Sale	62.65	4,688	293,703		Nov 07 04:36 PM
PAMELA CRAMER	Officer	Nov 06 '24	Proposed Sale	56.25	4,687	263,644		Nov 06 05:07 PM
GOOD JENNIFER L	Director	Sep 17 '24	Option Exercise	21.54	31,751	684,066	34,751	Sep 19 04:30 PM
GOOD JENNIFER L	Director	Sep 17 '24	Sale	52.40	31,751	1,663,803	3,000	Sep 19 04:30 PM
JENNIFER GOOD	Director	Sep 17 '24	Proposed Sale	49.52	31,751	1,572,310		Sep 17 04:42 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Option Exercise	19.02	4,099	77,963	17,599	Sep 11 04:32 PM
Cramer Pamela J.	Chief Human Resources Officer	Sep 09 '24	Sale	50.03	4,099	205,062	13,500	Sep 11 04:32 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Option Exercise	10.51	17,501	183,944	20,501	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Option Exercise	18.99	3,199	60,749	6,199	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 10 '24	Sale	49.65	17,501	868,923	3,000	Sep 11 04:31 PM
TETRAULT LYNN A.	Director	Sep 09 '24	Sale	50.04	3,199	160,068	3,000	Sep 11 04:31 PM
GOOD JENNIFER L	Director	Sep 09 '24	Option Exercise	13.34	37,241	496,706	40,241	Sep 11 04:30 PM
GOOD JENNIFER L	Director	Sep 09 '24	Sale	50.45	37,241	1,878,700	3,000	Sep 11 04:30 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Sep 10 '24	Proposed Sale	50.66	17,501	886,601		Sep 10 04:22 PM
JENNIFER GOOD	Director	Sep 09 '24	Proposed Sale	49.25	16,749	824,888		Sep 09 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Option Exercise	19.02	3,200	60,864	16,700	Aug 28 04:31 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 26 '24	Sale	50.01	3,200	160,018	13,500	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Option Exercise	18.99	4,300	81,657	7,300	Aug 28 04:31 PM
TETRAULT LYNN A.	Director	Aug 26 '24	Sale	50.01	4,300	215,029	3,000	Aug 28 04:31 PM
GOOD JENNIFER L	Director	Aug 26 '24	Option Exercise	18.63	14,508	270,322	17,508	Aug 28 04:30 PM
GOOD JENNIFER L	Director	Aug 26 '24	Sale	50.01	14,508	725,526	3,000	Aug 28 04:30 PM
JENNIFER GOOD	Director	Aug 26 '24	Proposed Sale	46.12	35,000	1,614,200		Aug 26 04:27 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 26 '24	Proposed Sale	46.12	7,499	345,854		Aug 26 04:27 PM
PAMELA CRAMER	Officer	Aug 26 '24	Proposed Sale	46.12	7,299	336,630		Aug 26 04:26 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Option Exercise	4.15	10,000	41,500	13,000	Aug 14 04:15 PM
TETRAULT LYNN A.	Director	Aug 12 '24	Sale	44.65	10,000	446,462	3,000	Aug 14 04:15 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Option Exercise	19.02	30,771	585,264	62,506	Aug 13 04:45 PM
Cramer Pamela J.	Chief Human Resources Officer	Aug 09 '24	Sale	45.15	49,006	2,212,498	13,500	Aug 13 04:45 PM
LYNN TETRAULT393 COMMONWEALTH	Director	Aug 12 '24	Proposed Sale	45.26	10,000	452,600		Aug 12 04:13 PM
PAMELA CRAMER	Officer	Aug 09 '24	Proposed Sale	45.87	49,006	2,247,905		Aug 09 04:09 PM
Cramer Pamela J.	Chief Human Resources Officer	Jul 29 '24	Sale	49.06	1,395	68,439	31,735	Jul 30 05:09 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Option Exercise	27.35	10,468	286,300	10,498	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 16 '24	Sale	53.00	10,468	554,817	30	Jul 18 05:59 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Option Exercise	21.38	5,313	113,592	5,343	Jul 16 04:30 PM
Shulman Joseph	Chief Technical Officer	Jul 12 '24	Sale	50.01	5,313	265,725	30	Jul 16 04:30 PM

NEO

Neogenomics Inc

RYTM

Rhythm Pharmaceuticals Inc

Upgrade your FINVIZ experience